Boffito M - Search Results

1

The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.

Penchala SD, Fawcett S, Else L, Egan D, Amara A, Elliot E, Challenger E, Back D, Boffito M, Khoo S. Penchala SD, et al. Among authors: boffito m. J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 1;1027:174-80. doi: 10.1016/j.jchromb.2016.05.040. Epub 2016 May 27. J Chromatogr B Analyt Technol Biomed Life Sci. 2016. PMID: 27290668

2

Undefined duration of opiate withdrawal induced by efavirenz in drug users with HIV infection and undergoing chronic methadone treatment.

Boffito M, Rossati A, Reynolds HE, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. AIDS Res Hum Retroviruses. 2002 Mar 20;18(5):341-2. doi: 10.1089/088922202753519115. AIDS Res Hum Retroviruses. 2002. PMID: 11897035 No abstract available.

3

Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens.

Boffito M, Sciole K, Raiteri R, Bonora S, Hoggard PG, Back DJ, Di Perri G. Boffito M, et al. Drug Metab Dispos. 2002 Jul;30(7):859-60. doi: 10.1124/dmd.30.7.859. Drug Metab Dispos. 2002. PMID: 12132432 No abstract available.

4

The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects.

Boffito M, Hoggard PG, Reynolds HE, Bonora S, Meaden ER, Sinicco A, Di Perri G, Back DJ. Boffito M, et al. Br J Clin Pharmacol. 2002 Sep;54(3):262-8. doi: 10.1046/j.1365-2125.2002.01663.x. Br J Clin Pharmacol. 2002. PMID: 12236846 Free PMC article.

5

Simultaneous determination of rifampicin and efavirenz in plasma.

Boffito M, Tija J, Reynolds HE, Hoggard PG, Bonora S, Di Perri G, Back DJ. Boffito M, et al. Ther Drug Monit. 2002 Oct;24(5):670-4. doi: 10.1097/00007691-200210000-00015. Ther Drug Monit. 2002. PMID: 12352941

6

Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring.

Boffito M, Back DJ, Hoggard PG, Caci A, Bonora S, Raiteri R, Sinicco A, Reynolds HE, Khoo S, Di Perri G. Boffito M, et al. AIDS. 2003 May 2;17(7):1107-8. doi: 10.1097/00002030-200305020-00029. AIDS. 2003. PMID: 12700470 No abstract available.

7

Protein binding in antiretroviral therapies.

Boffito M, Back DJ, Blaschke TF, Rowland M, Bertz RJ, Gerber JG, Miller V. Boffito M, et al. AIDS Res Hum Retroviruses. 2003 Sep;19(9):825-35. doi: 10.1089/088922203769232629. AIDS Res Hum Retroviruses. 2003. PMID: 14585213 Review.

8

Lopinavir protein binding in vivo through the 12-hour dosing interval.

Boffito M, Hoggard PG, Lindup WE, Bonora S, Sinicco A, Khoo SH, Di Perri G, Back DJ. Boffito M, et al. Ther Drug Monit. 2004 Feb;26(1):35-9. doi: 10.1097/00007691-200402000-00008. Ther Drug Monit. 2004. PMID: 14749547 Clinical Trial.

9

Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.

Ford J, Boffito M, Wildfire A, Hill A, Back D, Khoo S, Nelson M, Moyle G, Gazzard B, Pozniak A. Ford J, et al. Among authors: boffito m. Antimicrob Agents Chemother. 2004 Jul;48(7):2388-93. doi: 10.1128/AAC.48.7.2388-2393.2004. Antimicrob Agents Chemother. 2004. PMID: 15215085 Free PMC article. Clinical Trial.

10

Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen.

Boffito M, Dickinson L, Hill A, Back D, Moyle G, Nelson M, Higgs C, Fletcher C, Mandalia S, Gazzard B, Pozniak A. Boffito M, et al. Antivir Ther. 2004 Jun;9(3):423-9. Antivir Ther. 2004. PMID: 15259905 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

363 results

Search Page

Filters